(CNBC) AbbVie on Wednesday said it will acquire neuroscience drugmaker Cerevel Therapeutics for roughly $8.7 billion. Under the terms of the deal, AbbVie will pay $45 per share for Cerevel. AbbVie said it expects to complete the acquisition in the middle of 2024. Shares of Cerevel jumped 16% after the close Wednesday to nearly $43 per share, just below the purchase price.
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion
This entry was posted in Syndicated. Bookmark the permalink.
